SCHEMBL21252273

SCHEMBL21252273

COc1cc(OC)c(Cl)c(-c2cc3cnc(N)nc3c(N3CC(C)(OC)C3)n2)c1Cl

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 9/20 0.35
▸ FGFR2 P21802 5/20 0.35
▸ JAK2 O60674 2/20 0.35
▸ JAK1 P23458 2/20 0.35
▸ TYK2 P29597 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ JAK3 P52333 2/20 0.35
▸ AURKB Q96GD4 2/20 0.35
▸ NOS1 P29475 1/20 0.33
▸ FGFR4 P22455 4/20 0.33
▸ MAP3K12 Q12852 3/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ TTK P33981 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.31
▸ HSP90AB1 P08238 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21252266 0.93 JAK2 (0.36) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL24488375 0.92 FGFR1 (0.35) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL21252208 0.92 TTK (0.38) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL21251663 0.90 NOS1 (0.36) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL24488267 0.90 JAK2 (0.37) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL21252321 0.89 MAP3K12 (0.37) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL21251781 0.88 JAK2 (0.36) JAK2JAK1TYK2KDRJAK3
SCHEMBL21252291 0.87 TTK (0.41) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL21252229 0.87 NOS1 (0.35) FGFR1FGFR2JAK2JAK1TYK2
SCHEMBL21252417 0.87 MAP3K12 (0.35) FGFR1FGFR2JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3524603-B1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2022-06-08 — — EP disclosed
EP-3524603-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2019-08-14 — — EP disclosed
Send feedback